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The regulatory activities of mouse CD4
+Foxp3
+ T cells on various immune cells, including NK cells, have been well 
documented. Under some conditions, conventional CD4
+Foxp3
− T cells in the periphery are able to acquire inhibi-
tory function on other T cells, but their roles in controlling innate immune cells are poorly defined. As a potential 
cellular therapy for cancer, ex vivo activated CD4
+Foxp3
− effector T cells are often infused back in vivo to suppress 
tumor growth and metastasis. Whether such activated T cells could affect NK-cell control of tumorigenesis is unclear. 
In the present study, we found that mitogen-activated CD4
+Foxp3
− T cells exhibited potent suppressor function on 
NK-cell proliferation and cytotoxicity in vitro, and notably facilitated B16 melanoma metastasis in vivo. Suppression 
of NK cells by activated CD4
+Foxp3
− T cells is cell-cell contact dependent and is mediated by Qa-1:NKG2A interac-
tion, as administration of antibodies blocking either Qa-1 or NKG2A could completely reverse this suppression, and 
significantly inhibited otherwise facilitated melanoma metastasis. Moreover, activated CD4
+Foxp3
− cells from Qa-1 
knockout mice completely lost the suppressor activity on NK cells, and failed to facilitate melanoma metastasis when 
transferred in vivo. Taken together, our findings indicate that innate anti-tumor response is counter regulated by the 
activation of adaptive immunity, a phenomenon we term as “activation-induced inhibition”. Thus, the regulatory role 
of activated CD4
+Foxp3
− T cells in NK-cell activity must be taken into consideration in the future design of cancer 
therapies. 
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Introduction
Regulation is central to immune responses and im-
mune tolerance. Naturally-occurring CD4
+Foxp3
+ cells 
are considered to be one of the main types of T regu-
latory cells (Tregs), which are involved in regulating 
a wide range of activities including the responses to 
autoantigens, alloantigens, tumor antigens, pathogen-
derived antigens, and even the maintenance of normal 
pregnancy [1]. CD25 has been used as a traditional, 
albeit imperfect, marker for CD4
+Foxp3
+ Tregs. None-
theless, peripheral mature CD4
+CD25
− T cells can also 
be induced to acquire inhibitory function in vivo [2-7]. 
For example, both CD4
+CD25
+ and CD4
+CD25
− T cells 
from tolerant mice could mediate suppression, although 
CD4
+CD25
+ T cells were more efficient than CD4
+CD25
− www.cell-research.com | Cell Research
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T cells [8]. CD4
+CD25
− T cells activated by anti-CD3 
monoclonal antibody were able to inhibit the activation 
and proliferation of bystander CD4
+ T cells in a cell 
contact-dependent manner, reversible by exogenous IL-2 
and anti-Glucocorticoid Induced Tumor Necrosis Fac-
tor Receptor (GITR) [9]. In some of these studies when 
Foxp3 expression was examined, CD4
+CD25
− T cells 
are still Foxp3
+ [5, 7], whereas in others, they are clearly 
Foxp3
− [6]. These data suggest that T cells with regula-
tory activities are likely to be extremely diverse, but it 
is not clear how such diverse regulatory T cells assume 
common responsibility in regulating productive immune 
responses, which often involve cells in both adaptive and 
innate immune systems. 
NK cells are one of the most important innate immune 
cells for protection against virus infection and tumor 
growth [10], and are best characterized by their ability of 
cytotoxicity towards target cells without pre-activation 
and immunoregulatory cytokine production [11, 12]. NK-
cell activation induced by a set of defined surface recep-
tors has been well elucidated [12, 13]. However, signals 
delivered to NK cells from other cells, especially from 
adaptive immune cells, have not been adequately stud-
ied. The anatomical proximity of NK cells and T cells 
increases the probability of direct interactions between 
them [14]. Several recent studies show that naturally oc-
curring CD4
+CD25
+ T cells could inhibit NK-cell func-
tion through TGF-β1, most likely in its membrane-bound 
form [15-17]. However, there is no evidence regarding 
the influence of activated CD4
+CD25
− T cells on NK-cell 
function. In the present study, we polyclonally activated 
Treg-depleted CD4
+CD25
− T cells with Concanavalin 
A (Con A), and examined the effects of pre-activated 
CD4
+CD25
− T cells on NK-cell-mediated cytotoxicity 
both in vitro and in vivo. Our data indicate that activated 
CD4
+CD25
− T cells dampen NK-cell cytotoxicity and 
facilitate melanoma metastasis via Qa-1-dependent path-
way.
Results
Activated CD4
+ T cells exhibited potent inhibitory effect 
on NK-cell cytotoxicity and proliferation
To determine the impact of activated CD4
+ effec-
tor T cells on NK-cell cytotoxicity, we MACS-purified 
CD4
+CD25
− T cells, stimulated with Con A, and then co-
cultured them with freshly isolated syngeneic NK cells 
in an in vitro 
51Cr-release cytotoxicity assay. We found 
that activated T cells, but not resting T cells, significantly 
inhibited NK-cell cytotoxicity. NK-cell lysis of YAC-1 
target cells was inhibited by as much as 32% in the pres-
ence of activated CD4
+ effector T cells (Figure 1A). 
To test whether activated CD4
+ T cells could also 
inhibit NK-cell cytotoxicity in vivo, we adoptively trans-
ferred syngeneic resting or Con A-activated CD4
+ T cells 
into BALB/c nude mice, which are athymic and lack of 
mature T cells. After 3 days, NK cells in the spleen were 
harvested to measure their cytotoxicity towards YAC-1 
cells. Strikingly, cytotoxicity of NK cells from BALB/
c nude mice receiving activated, but not resting, CD4
+ T 
cells was reduced by 58% as compared to that from mice 
receiving saline control (Figure 1B). 
To assess whether activated CD4
+ T cells could exert 
an inhibitory effect on NK-cell proliferation, we stimu-
lated NK cells with exogenous IL-2 (100 U/ml) alone or 
together with resting or Con A-activated CD4
+ effector 
T cells. These T cells were fixed with 0.5% glutaralde-
hyde post-activation to prevent thymidine incorporation 
by themselves. Compared to the medium, IL-2 potently 
stimulated NK-cell proliferation. However, in the pres-
ence of activated T cells, IL-2-stimulated NK-cell prolif-
eration was significantly inhibited. In contrast, resting T 
cells fixed with 0.5% glutaraldehyde did not apparently 
affect IL-2-stimulated NK-proliferation (Figure 1C).
Because activated T cells expressing IL-2 receptors 
could compete with NK cells for IL-2, we measured IL-2 
concentrations in the supernatants of NK-T-cell co-cul-
tures in the absence of exogenous IL-2. The data showed 
that there were no significant differences between the 
groups added with resting or Con A-activated T cells 
(Figure 1D).
As CD4
+CD25
− T cells are a mixture of naïve, effec-
tor, memory and small number of contaminating Foxp3
+ 
regulatory T cells, we used Foxp3GFP knockin mice 
to FACS-sort CD4
+Foxp3
−CD62L
+ naïve T cells and 
CD4
+Foxp3
+ Treg cells based on GFP expression, and 
tested their effects on NK cytotoxicity. Compared to rest-
ing CD4
+Foxp3
−CD62L
+ naïve T cells, Con A-activated 
naïve T cells were found to inhibit NK cytotoxicity by 
31% (Figure 1E, bar 2 vs. bar 1, P = 0.001). Even at 10-
fold less cell number (NK:Treg = 1:1) than activated 
naïve T cells (NK:T = 1:10), CD4
+Foxp3
+ Treg cells po-
tently inhibited NK cytotoxicity by 56% (Figure 1E, bar 
3 vs. bar 1, P < 0.001). This suggests that activated naïve 
T cells may inhibit NK cytotoxicity in a mechanism dif-
ferent from that by Foxp3
+ Treg cells. 
Adoptive transfer of activated CD4
+ T cells facilitated 
melanoma metastasis in SCID mice through suppressing 
NK-cell function
Because of the crucial role of NK cells in prevent-
ing tumorigenesis, we tested whether activated CD4
+ T 
cells could affect NK-cell control of tumor growth and 
metastasis. We set up a B16 melanoma model in SCID Activated CD4 cells inhibit NK via Qa-1
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Figure 1 The effect of activated CD4
+ T cells on NK-cell cytotoxicity and proliferation. (A) Activated CD4
+ T cells inhibited NK-
cell function in vitro. NK cells were co-cultured with target YAC-1 cells alone, or in the presence of either resting CD4
+CD25
− 
T cells or CD4
+CD25
− T cells activated overnight with Concanavalin A (10 µg/ml). Data are shown as mean percentages of 
51Cr release (± SD) after 48 h in vitro culture, and are representative of three independent experiments. (B) Activated CD4
+ T 
cells inhibited NK-cell function in vivo. Nude mice (n = 3/group) were injected twice with saline or 2 × 10
6 of either resting or 
Con A-activated syngeneic CD4
+CD25
− T cells on days 0 and 1. On day 4, cytolytic activities of splenocytes on YAC-1 cells 
were determined ex vivo by 
51Cr release assay. Data are shown as mean percentages of 
51Cr release (±SD), and are repre-
sentative of three independent experiments. (C) Activated CD4
+ T cells inhibited NK-cell proliferation in vitro. Freshly isolated 
NK cells were stimulated with 100 U/ml IL-2, with or without the fixed (0.5% glutaraldehyde) Con A-activated CD4
+ T cells. 
NK-cell proliferation was analyzed after 96 h by 
3H-thymidine incorporation. The data are representative of three independent 
experiments. (D) IL-2 concentrations assayed in NK-T-cell co-culture. NK cells were co-cultured with either Con A-activated 
or resting T cells without exogenous IL-2 for 24 h. IL-2 concentrations in the supernatants were determined by mouse IL-2 
ELISA kit. Data are representative of three independent experiments. (E) Con A-activated CD4
+Foxp3
−CD62L
+ T cells inhib-
ited NK cytotoxicity in vitro. CD4
+Foxp3
−CD62L
+ T cells were sorted from mononuclear cells by FACS and then activated by 
Con A (10 µg/ml). Meanwhile, CD4
+Foxp3
+ T cells were sorted by FACS and served as control. Each type of FACS-sorted 
cells was co-cultured with NK cells. NK cytotoxicity was determined by FACS as described in Materials and Methods. The 
data are representative of two independent experiments. 
mice, and adoptively transferred either resting or Con 
A-activated CD4
+ T cells at the time of tumor cell in-
oculation. Compared to saline-treated control group, the 
number of metastatic melanoma nodules in the lung was 
significantly higher in the mice receiving activated, but 
not resting, CD4
+ T cells (Figure 2A). Histological ex-
amination confirmed the gross observation by eye (Figure 
2B). Compared to saline, transferred resting CD4
+ T cells 
did not exhibit beneficial effect in this melanoma lung 
metastasis model, although they did provide protection 
in a liver metastasis model [18]. 
To determine whether NK cells were involved in the 
facilitation of melanoma metastasis by activated CD4
+ 
T cells, we depleted NK cells with antibody PK136. www.cell-research.com | Cell Research
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The results showed that NK-cell depletion markedly 
enhanced tumor metastasis into the lung (Figure 3A and 
3B). Under these conditions, adoptively transferred ac-
tivated CD4
+ T cells did not significantly influence the 
growth and metastasis of tumor cells (Figure 3A and 
3B), suggesting that suppression of NK-cell function was 
involved in activated CD4
+ T cell-facilitated melanoma 
metastasis. To further dissect the effect of transferred T 
cells from endogenous T and B cells on NK cells, RAG-
1
−/− mice were used as recipients of adoptive T-cell trans-
fer. The results showed that although RAG-1
−/− mice are 
more resistant to melanoma metastasis due to heightened 
NK-cell activities, transfusion of Con A-activated T cells 
compromised such innate immunity, and dramatically 
facilitated melanoma metastasis in the RAG-1
−/− mice 
(Figure 3C and 3D).
Activated CD4
+ T cells are Foxp3
−, and their suppres-
sion on NK-cell cytotoxicity was TGF-β and adenosine 
independent
In several different experiments, after stimulation with 
Con A in the presence of APC, about 20%-50% of FACS-
sorted CD4
+Foxp3(GFP)
− T cells became CD25-positive. 
However, these activated CD4
+ T cells did not express 
Foxp3 (Figure 4A). Thus, activated naïve CD4
+ T cells 
can suppress NK-cell function in a manner independent 
of Foxp3 expression. 
To test whether like CD4
+Foxp3
+ Tregs, activated 
CD4
+Foxp3
− T cells could suppress NK cytotoxicity via 
TGF-β, we added antibodies against TGF-β1 into the co-
culture. Still, neutralizing TGF-β1 failed to reverse the 
inhibitory effect of activated T cells on NK-cell cytotox-
icity (Figure 4B). Another recently revealed mechanism 
of Treg action is that by co-expressing ecto-enzymes 
CD39 (ectonucleoside triphosphate diphosphohydro-
lase-1; EC 3.6.1.5) and CD73 (ecto-5′-nucleotidase; EC 
3.1.3.5), Tregs can hydrolyze ATP/ADP into AMP and 
eventually to adenosine, which is immunosuppressive 
[19]. We thus FACS-sorted CD4
+Foxp3(GFP)
− cells from 
Foxp3GFP knockin mice, stimulated them with Con 
A in the presence of syngeneic APC, and after activa-
tion re-sorted the activated CD4
+Foxp3(GFP)
− cells and 
tested whether they did produce adenosine. The result 
showed that both natural Treg (nTreg) and in vitro TGF-
β-induced Treg (iTreg) produced copious amounts of 
adenosine, whereas Con A-activated CD4
+Foxp3
− T cells 
failed to maintain a meaningful pool of adenosine, even 
though their CD39 enzymatic activity was increased to 
catalyze ADP→AMP (Figure 4C). In fact, upon activa-
tion, elevated CD39 activity can be observed also in 
CD4
+Foxp3(GFP)
− cells activated by plate-bound anti-
CD3/CD28 (data not shown), but these cells do not pro-
duce adenosine as they do not express CD73 [19]. There-
fore, adenosine-mediated immunoregulation, which con-
tributes to Treg suppressive activity, is not responsible 
for NK suppression by activated CD4
+Foxp3
− T cells.
Activated CD4
+Foxp3
− T cells suppress NK-cell cytotox-
icity via Qa-1
In mice, the nonpolymorphic major histocompatibility 
complex class Ib molecule Qa-1 is the homolog of hu-
man leukocyte antigen E (HLA-E), which forms a het-
erodimer with β2-microglobulin that presents peptides 
derived in TAP-dependent fashion from the major histo-
compatibility complex class Ia leader sequences (Qdm) 
and other self and foreign antigens [20-22]. The interac-
tion between Qa-1 and nonclonally distributed NK cell 
inhibitory receptor CD94-NKG2A could dampen the cy-
totoxicity of NK cells and a subpopulation of CD8
+ CTL 
Figure 2 Activated CD4
+ T cells facilitated B16 melanoma me-
tastasis in SCID mice. Sex- and age-matched SCID mice were 
injected with 2.5 × 10
5 B16 tumor cells via tail vein on day 0. 
On days 1 and 3, 10
6 of resting or Con A-activated CD4
+ T cells 
were adoptively transferred (i.v.). The control group was injected 
with an equal volume of saline. Tumor metastasis was assessed 
on day 10 in the lung. (A) Metastatic nodules on the lung sur-
face were quantified with the aid of a dissecting microscope. 
Data are recorded as mean ± SD (n = 5), and Student’s t test 
is used to compare saline and cell transfer groups. The results 
are representative of two independent experiments including 
five mice in each group. (B) Histological examination (HE stain-
ing, ×100) of melanoma formation in lung tissues confirmed that 
there was a significantly increased number of visible melanoma 
nodules on the lung surface (insets) in mice transferred with 
activated CD4
+ T cells (bottom), as compared with those treated 
with saline (upper). Activated CD4 cells inhibit NK via Qa-1
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[23]. Moreover, Qa-1 has been reported to be induced on 
Con A-activated splenic T cells [24]. We therefore tested 
in our system whether activated CD4
+Foxp3
− T cells sup-
press NK-cell cytotoxicity via Qa-1. Indeed, anti-Qa-1-
blocking antibody could reverse the inhibitory effect of 
activated CD4
+ T cells on NK-cell lytic activity against 
target cells in vitro (Figure 5A, left panel). As NKG2A 
is the ligand of Qa-1, we thus analyzed the expression 
of NKG2A on NK cells. Around 51.6% of CD3
−NK1.1
+ 
NK cells were NKG2A-positive (Figure 5B). Similar to 
blocking Qa-1, blocking NKG2A was also able to re-
verse the inhibitory effect of activated CD4
+ T cells on 
NK cytotoxicity (Figure 5A, right panel). 
We then administered anti-Qa-1 together with Con A-
activated CD4
+Foxp3
− T cells into SCID mice, and tested 
NK-cell cytotoxicity in vivo after 24, 48 and 72 h. The 
result showed that NK-cell function suppressed by adop-
tively transferred activated CD4
+ T cells could be rein-
stated after infusion of anti-Qa-1 antibody (Figure 5C). 
We further performed in vivo experiments in the tumor 
model, where SCID mice inoculated with B16 melanoma 
cells were transferred with Con A-activated CD4
+Foxp3
− 
T cells, together with or without anti-Qa-1 antibody. 
Strikingly, melanoma metastasis enhanced by activated 
T cells was almost completely blocked by anti-Qa-1, as 
shown by the significantly reduced number of metastatic 
Figure 3 Activated CD4
+ T cells facilitated melanoma metastasis through suppressing NK-cell function. Inoculation of B16 
melanoma cells (on day 0) and transfer of Con A-activated CD4
+ T cells into SCID or RAG-1
−/− mice was carried out as de-
scribed in Materials and Methods. NK cell depletion antibody (PK136) was injected (i.p.) on days -1, 0 and 1. (A) The visible 
melanoma metastatic nodules on the lung surface were counted on day 10. After NK cell depletion, there was no longer sig-
nificant difference in tumor metastasis between animals treated with saline or activated T cells. Data are recorded as mean 
± SD (n = 5), and student’s t test is used to compare saline and cell transfer groups. (B) Histological examination (HE stain-
ing, ×100) of melanoma formation in lung tissues of mice with (bottom) or without (upper) NK cell depletion. Photo insets 
are representative of five animals of each group. (C) Sex- and age-matched RAG-1
−/− mice were injected with 2 × 10
5 B16 
tumor cells via tail vein on day 0. On days 1 and 3, 10
6 of resting or Con A-activated CD4
+Foxp3
− T cells were adoptively 
transferred. Tumor metastasis was assessed on day 10 on the lung surface. Data are recorded as mean ± SD (n = 6), and 
Student’s t test is used to compare the groups receiving resting or Con A-activated CD4
+Foxp3
− T cells. (D) Representative 
photos of dissected lungs in C. www.cell-research.com | Cell Research
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nodules in the lungs of mice that received the antibody 
than those did not (Figure 5D-5E). In addition to Qa-1 
blocking antibody, we used Qa-1 knockout mice to dem-
onstrate the involvement of Qa-1 in NK-cell inhibition. 
In vitro, activated CD4
+Foxp3
− T cells from Qa-1 knock-
out mice were unable to inhibit NK cytotoxicity (Figure 
5F). Furthermore, adoptive transfer of Con A-activated 
Qa-1 knockout T cells into RAG-1
−/− mice bearing mela-
noma did not favor melanoma metastasis as their wild-
type counterpart did (Figure 5G-5H). These data strongly 
support the notion that activated T cells could facilitate 
tumor development via Qa-1-dependent suppression of 
NK cytotoxicity. 
Discussion
Innate and adaptive immunity are two categories of 
immune responses with an interdependent and interactive 
relationship that maintains the homeostasis of the body. 
Accumulating clinical and experimental data have dem-
onstrated that the adaptive immune lymphocytes not only 
provide reinforcement to the ongoing innate response, 
but also under certain circumstances act as negative reg-
ulators in the innate response [25-27]. 
Naturally-occurring CD4
+Foxp3
+ T cells are consid-
ered to be one of the main regulatory cell types, which 
inhibit the proliferation and effector functions of a large 
panel of immune cells [17]. Besides the thymus-derived 
Foxp3
+ natural Tregs, conditionally-induced T regulatory 
cells type 1 (Tr1) and Th3 cells are generally regarded as 
distinct populations following peripheral immune activa-
tion [28]. In vitro, Tr1 cells derive from repetitive stimu-
lation in the presence of IL-10. They are anergic, Foxp3
−, 
but can suppress immune responses via cell-cell contact 
and/or the production of high levels of IL-10 and TGF-β 
[29]. Th3 cells cloned from orally tolerized mice produce 
high amounts of TGF-β, low amounts of IL-4 and IL-10, 
but no IFN-γ or IL-2 upon TCR ligation, and suppressed 
EAE in a TGF-β-dependent fashion [30]. Because of the 
intimate role of TGF-β in Foxp3 induction, the boundary 
Figure 4 Suppression of NK cytotoxicity by activated CD4
+ T cells was Foxp3, TGF-β and adenosine independent. (A) Flow 
cytometry analysis of GFP(Foxp3) in resting (left panel) and Con A-activated (right panel) CD4
+CD25
− T cells from Foxp3GFP 
knockin mice. (B) Inhibition of NK-cell cytotoxicity by Con A-activated CD4
+Foxp3
− T cells was TGF-β independent. NK cy-
totoxicity in the presence of Con A-activated CD4
+Foxp3
− T cells was compared with or without anti-TGF-β1 added into the 
co-culture system. Data are shown as mean percentages of 
51Cr release (±SD) and are representative of three independent 
experiments. (C) Hydrolysis of extracellular 
14C-radiolabeled ADP to adenosine was catalyzed by natural and TGF-β-induced 
CD4
+Foxp3
+ Tregs (Panels 1 and 3). Resting or Con A-activated CD4
+Foxp3
− T cells did not generate immunosuppressive 
adenosine (Panels 2 and 4).Activated CD4 cells inhibit NK via Qa-1
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Figure 5 Suppression of NK-cell cytotoxicity by Con A-activated CD4
+Foxp3
− T cells was Qa-1 dependent. (A) Anti-Qa-1 or 
anti-NKG2A antibody abrogated the suppression of activated CD4
+ T cells on NK-cell cytotoxicity in vitro. Data shown are 
representative of three independent experiments. (B) Percentage of NKG2A-positive cells in the NK population. (C) Qa-1 
antibody could reverse the inhibition of NK function by activated CD4
+ T cells in vivo. SCID mice (n = 3/group) were injected 
with saline or Con A-activated CD4
+Foxp3
− T cells (Act. T) or Act. T plus anti-mouse Qa-1 antibody. At the indicated times, cy-
tolytic activities of splenocytes were determined ex vivo in a 
51Cr release assay. (D) Metastatic nodules on the lung surface of 
animals treated with activated CD4
+ T cells in the presence or absence of anti-Qa-1. Data were recorded as mean ± SD, and 
the Student’s t test was used to compare between groups. (E) Photos of dissected lungs from the two groups (n = 5/group) in D. 
The visible melanoma nodules on the lung surface were significantly reduced in animals treated with anti-Qa-1 as compared 
with those non-treated. (F) Con A-activated T cells from Qa-1 knockout mice lost their inhibitory function on NK cytotoxicity 
in vitro. Data were mean ± SD, and representative of two independent experiments. (G) Con A-activated CD4
+Foxp3
− T cells 
from Qa-1 knockout mice failed to facilitate B16 melanoma metastasis in RAG-1
−/− mice. Sex- and age-matched RAG-1
−/− 
mice were injected with B16 melanoma cells via tail vein one day before transferring resting or activated CD4
+Foxp3
− T cells 
from wild-type or Qa-1 knockout mice. Ten days later, tumor metastasis was assessed by counting melanoma nodules on the 
lung surface. Error bars indicate mean ± SD (n = 6) and statistical significance was tested by Student’s t test. (H) Photos of 
dissected lungs from the 4 groups (n = 6/group) in G. There was a significantly decreased number of visible melanoma nod-
ules on the lung surface in Qa-1 knockout mice as compared with those wild-type animals.www.cell-research.com | Cell Research
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between Foxp3
+ Tregs and Th3 cells becomes less clear. 
Transient overexpression of TGF-β upon TCR ligation 
differentiates antigen-specific Th0 cells into regulatory 
Foxp3
+CD25
+/− Th3 cells in vitro. Repetitive antigen 
stimulation results in sustained expression of Foxp3 in 
Th3 cells that acquire regulatory function independent of 
surface expression of CD25 [31, 32].
In addition to these well-documented regulatory 
cell types, we observed that pre-activated CD4
+CD25
− 
T cells, being Foxp3
− as examined by intracellular 
Foxp3 staining and by using Foxp3GFP mice, counter-
intuitively suppressed NK cytotoxicity, suggesting that 
fully stimulated effector T cells may act, under certain 
conditions, as a type of regulatory cells to restrain NK 
activity. The mechanism underlying such regulation in-
volves Qa-1. Although Qa-1 mRNA can be detected in 
many cell types, surface expression of functional Qa-
1-β2-microglobulin heterodimer is only detectable on 
activated T, B lymphocytes and dendritic cells [22, 33]. 
In line with this, Con A-activated T cells were reported 
to express Qa-1 molecule [24]. Dissection of the NK-cell 
population revealed that the NKG2A
+ but not NKG2A
− 
subset of NK-cells-mediated lysis of Qa-1-deficient CD4 
cells. Antibody blockage of Qa-1:NKG2A interaction re-
sulted in potent NK-dependent elimination of activated-
autoreactive T cells and amelioration of autoimmune 
EAE [34]. These findings emphasize that the interaction 
between Qa-1 on activated T cells and NKG2A on NK 
cells protects activated T cells from NK lysis and is es-
sential for clonal expansion and development of immu-
nologic memory. 
However, Qa-1:NKG2A interaction may function as 
a double-edged sword, i.e., activated T cells through 
expression of Qa-1 can disarm NK cells via the NKG2A 
inhibitory receptor. Our data in a simplified adoptive 
transfer model showed that blockade of Qa-1:NKG2A 
interaction liberated NK cells from the inhibitory action 
of activated CD4
+ T cells, and restored otherwise sup-
pressed NK control on tumor metastasis. Obviously, the 
role of Qa-1:NKG2A interaction in tumor immunity in 
immunocompetent hosts is very complicated, as we were 
surprised that, compared to wild-type animals, metastasis 
of B16 melanoma cells in Qa-1 knockout mice was dra-
matically enhanced (data not shown). Recently, Lu et al. 
[34] found that Qa-1-deficient CD4 cells failed to under-
go antigen-induced or homeostatic expansion due to in-
creased susceptibility to NK cell lysis. Re-expression of 
Qa-1-Qdm on autoreactive CD4 cells rescued expansion 
of self-reactive T cell clones. Whether Qa-1 deficiency 
negatively affects APC-T cell priming and activation, 
needs to be further studied.
Infusion of ex vivo activated tumor-specific T cells 
back into the tumor-bearing host has been attempted in 
the treatment of cancer patients [35-37], but its thera-
peutic capacity is marginal. For example, in a Phase I 
study, even when 6 billion of tumor-reactive CTLs were 
transferred back to melanoma patients every 2-3 weeks, 
there was only a modest clinical benefit with disease 
stabilization in roughly half of the cases. There were no 
formal partial clinical responses (defined as >50% reduc-
tion in cross-sectional area of all measurable metasta-
ses) or complete responses (defined as regression of all 
measurable metastatic disease) [38]. One of the reasons 
responsible for the poor clinical response is believed to 
be the higher prevalence of CD4
+Foxp3
+ Tregs at the 
tumor microenvironment, which potently suppresses NK 
and other immune cells [39]. Our study raised another 
intriguing possibility that fully stimulated, Qa-1-express-
ing, CD4
+Foxp3
− effector T cells (or CD8
+ CTLs) when 
adoptively transferred in vivo might also suppress the tu-
moricidal activities of NK cells. Such suppression is con-
ditional, i.e., dependent on the net outcome of negative 
and positive signals provided by T cells, such as T-cell-
derived stimulatory cytokines for NK cells (IL-2 [14] and 
IFN-γ). Our finding that Con A-activated CD4
+Foxp3
− T 
cells fixed by formalin to block secretion possessed even 
higher inhibitory capacity than those unfixed ones (data 
not shown) supports this view.
For cancer biotherapy, most strategies aimed to exploit 
the highly specific nature of adaptive immune responses 
do not work well as predicted. We caution that this may 
be because the feedback control by adaptive cells on in-
nate cells is not adequately considered. If attention is 
solely drawn to enhancing T cells while neglecting the 
potential “activation-induced inhibition”, one may inad-
vertently blunt innate immunity against tumor. On the 
other hand, our finding on the involvement of Qa-1, a 
specific molecule underpinning this “activation-induced 
inhibition”, may provide opportunities for further manip-
ulation. For instance, it can be envisioned that anti-Qa-1 
may function as an immune-enhancer if co-administered 
with ex vivo expanded anti-tumor T cells. Such manipu-
lation, nevertheless, needs to be carefully controlled by 
dose and timing, lest any possible negative effects on 
APC-T cell priming, as well as unleashed overzealous in-
nate responses that could sometimes lead to pathological 
consequences [25]. 
In summary, we demonstrated for the first time that 
activated CD4
+Foxp3
− T cells could attenuate tumor sur-
veillance by inhibition of NK cytotoxicity in membrane 
Qa-1-dependent manner. This activated CD4
+Foxp3
− 
“suppressor” T cell population is distinct from previously 
known natural and induced regulatory T cells based on 
their different regulatory mechanisms. We therefore re-Activated CD4 cells inhibit NK via Qa-1
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fer this phenomenon as “activation-induced inhibition”, 
which provides a new link between T and NK cells. 
These findings challenge the current dogma that adoptive 
transfer of activated autologous T cells favors the host 
for fighting against tumors. 
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good 
animal practice as defined by the relevant national and/or local 
animal welfare bodies, and all animal studies were approved by 
IACUC at both the Third Military Medical University (protocol #: 
SCXK20070003) and Beth Israel Deaconess Medical Center, Bos-
ton, USA (protocol #: 053-2008).
Animals
Wild-type, nude and SCID mice in BALB/c background were 
purchased from the Experimental Animal Department of the Third 
Military Medical University, Chongqing, China. Qa-1 knockout 
mice in C57BL/6 background were reported previously [34], and 
were kind gifts from Dr Harvey Cantor (Dana-Faber Cancer Insti-
tute, USA). Foxp3GFP knockin mice (C57BL/6) were generated 
as previously reported [40]. RAG-1
−/− mice (C57BL/6) were pur-
chased from Model Animal Research Center of Nanjing Univer-
sity, China. All animals were maintained under specific pathogen-
free conditions and used at 6-8 weeks of age. 
Cell preparation
All the cells used in the experiments were obtained from mouse 
spleens. Live, single cell suspensions were prepared by Ficoll 
density gradient centrifugation after lysing erythrocytes. The nega-
tive enrichment strategy was used for isolation of CD4
+CD25
− 
T cells following depletion of CD4
+CD25
+ T cells with mouse 
Treg isolation kit (Miltenyi, Germany). CD4
+Foxp3
+(GFP
+), 
CD4
+Foxp3
−(GFP
−) cells and CD4
+Foxp3
−CD62L
+ (GFP
−CD62L
+) 
cells were sorted by FACS from Foxp3GFP knockin mice. NK 
cells were isolated from BALB/c splenocytes by magnetic cell 
separation using the NK cell isolation kit (Miltenyi). The purity 
of each cell type was determined by FACS with PE- or FITC-
conjugated antibodies against CD3, CD4, CD25 and CD49b, and 
was typically > 95%.
Detection of intracellular Foxp3 expression
Foxp3 protein was detected by using a mouse Regulatory T cell 
Staining Kit (eBioscience, USA), according to the manufacturer’s 
instructions. Briefly, BALB/c splenocytes were surface-stained 
with FITC-conjugated anti-CD4 and APC-conjugated anti-CD25, 
followed by intracellular staining with PE-conjugated anti-Foxp3. 
PE-labeled Rat IgG2a served as an isotype control. Cells were then 
washed and analyzed by FACS. In some experiments when Fox-
p3GFP knockin mice were used, Foxp3 expression was tracked by 
GFP expression in flow cytometry.
Adenosine generation assay
CD4
+Foxp3
+(GFP
+) and CD4
+Foxp3
−(GFP
−) cells were FACS-
sorted from Foxp3GFP knockin mice [40], and used as resting 
natural Tregs (nTreg) and effector T cells (Teff), respectively. For 
cell activation, Teff cells were stimulated with plate-bound anti-
CD3 (10 µg/ml) and soluble anti-CD28 (1 µg/ml) in the presence 
of TGF-β (5 ng/ml) to generate induced Tregs (iTreg) [41]. Teff 
cells were also stimulated with anti-CD3/CD28 alone or with 10.0 
µg/ml Concanavalin A (Sigma, USA) in the presence of syngeneic 
T-cell-depleted splenocytes for 3 days. At the end of culture, vi-
able GFP
+ (iTreg) or GFP
− (activated Teff) cells were again FACS-
sorted. All the cell populations (2 × 10
5) were added with 
14C-ADP 
at 2.0 mCi/ml (GE Healthcare, USA). At the indicated times, ali-
quots were removed and analyzed for the presence of 
14C-ADP hy-
drolysis products by thin layer chromatography (TLC), as reported 
previously [19].
NK-cell cytotoxicity assay
A standard 
51Cr-release method was used to assay NK-cell cy-
totoxicity [42]. Briefly, YAC-1 cells (China Cell Storage Center) 
were labeled with 
51Cr in RPMI-1640 growth medium. NK cells 
and YAC-1 cells were added in triplicate into a 96-well plate at an 
Effector:Target (E:T) ratio of 100:1 for 4 h at 37 °C. In some ex-
periments, freshly isolated NK cells and target cells were co-cul-
tured with activated CD4
+ T cells at a ratio (NK:T) of 1:10 alone 
or in the presence of 10 µg/ml blocking antibodies against CD25 
(BD Biosciences), TGF-β1 (R&D Systems), NKG2A or Qa-1 (both 
from Santa Cruz). In comparison, freshly isolated NK cells were 
also co-cultured with natural Treg cells (CD4
+GFP
+) at the ratio 
of 1:1. IL-2 concentrations in the supernatants from the co-culture 
were determined with an ELISA Kit (R&D Systems). NK-cell cy-
totoxicity was determined 24 h post co-culture. For that, radioac-
tivities of the supernatants were measured by a γ-counter (Shanghai 
Medical Instrument Company, China). The spontaneous release 
and maximal release controls were also set up [42]. Specific cyto-
toxicity was calculated as follows: 
Percent 
51Cr Release = (cpm experimental − cpm spontaneous 
release)/(cpm maximum release − cpm spontaneous release) × 100
The inhibition by different subsets of T cells on NK-cell cyto-
toxicity was calculated as follows: 
Percent Inhibition = (Percent 
51Cr Release of experimental 
group − Percent 
51Cr Release of control group)/Percent 
51Cr Re-
lease of control group × 100 
NK-cell cytotoxicity on YAC-1 target cells was also measured 
by FACS. Briefly, target cells were stained with CFSE (5.0 µM) 
for 10 min. NK cells were co-cultured with CFSE-labeled YAC-
1 cells at a ratio of 100:1 for 3 h at 37 °C, 5% CO2. Target cell 
killing was determined by FACS on the basis of PI uptake. Per-
cent cytotoxicity = (Number of CFSE
+PI
+ cells)/(Number of total 
CFSE
+ cells) × 100 [42].
NK-cell proliferation assay
Activated CD4
+CD25
− T cells and resting CD4
+CD25
− T cells 
were fixed with 0.5% glutaraldehyde, carefully washed with PBS, 
and co-cultured with NK cells in 96-well U-bottom plates in the 
presence of IL-2 (100 U/ml) for 96 h at 37 °C in a 5% CO2 incuba-
tor. Cells were pulsed with 
3H-TdR (0.2 µCi per well) 8 h before 
harvest. Radioactivity of each sample in triplicate (means ± SD) 
was determined by a liquid scintillation counter (Beckman, USA).
Adoptive transfer of activated T cells
Isolated BALB/c CD4
+CD25
− T cells were incubated with Con 
A (10 µg/ml) in the presence of syngeneic T-cell-depleted spleno-
cytes for 48 h. Then, purified 1.5 × 10
6 Con A-activated CD4
+ T www.cell-research.com | Cell Research
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cells or naïve CD4
+CD25
− T cells were injected on days 0 and 2 
via the tail vein into BALB/c nude mice. Same volume of saline 
was injected into control mice. 24 h later, NK cells were harvested 
from the spleen, and the cytotoxicity of NK cells against YAC-1 
cells was tested as described above. 
B16 melanoma metastasis in SCID and RAG-1
−/− mice
As described previously [15], 2 × 10
5 B16 tumor cells were in-
jected into either SCID or RAG-1
−/− mice and wild-type C57BL/6 
mice via the tail vein on day 0. On days 1 and 3, 10
6 Con A-
activated or resting T cells were infused into mice. On day 10, 
mice were sacrificed and lung metastasis of B16 tumor cells was 
determined by quantifying the melanoma nodules. In some experi-
ments, depletion of NK cells in SCID mice [43] was achieved by 
injecting (i.p.) 100 µg of anti-NK1.1 (PK136) monoclonal anti-
body on days –1, 0 and 1 of tumor cell inoculation. 
In vivo administration of antibodies
For each mouse, a total of 200 µg anti-Qa-1 (Santa Cruz, 
clone 6A8.6F10, mouse IgG1) or anti-NKG2A (Santa Cruz, clone 
16A11, mouse IgG2b) was injected (i.v.) on day 0 of transferring 
T cells or tumor cells. The cytotoxicity of purified splenic NK 
cells against YAC-1 cells was tested after 24, 48 and 72 h. Lung 
metastasis of B16 tumor cells was determined by counting the 
melanoma nodules on day 10.
Statistics
Results were expressed as means ± SD. Data were analyzed 
with Student’s t test and Difference Square Analysis where appro-
priate. P < 0.05 was considered significant.
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